SCHEMBL22212866

SCHEMBL22212866

C/C(=N\C(C)(C)C)c1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
TDP1 Q9NUW8 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
MAPK1 P28482 1/20 0.41
STAT3 P40763 1/20 0.41
STAT1 P42224 1/20 0.41
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.37
PKM P14618 2/20 0.37
HTT P42858 2/20 0.37
ATM Q13315 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
HPGD P15428 1/20 0.37
NLRP1 Q9C000 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751736 1.00 ALDH1A1 (0.41) ALDH1A1LMNACES2CES1TDP1
SCHEMBL17298685 0.80 CYP19A1 (0.45) ALDH1A1LMNASMN1; SMN2NPC1MAPT
SCHEMBL24769893 0.80 SMN1; SMN2 (0.50) ALDH1A1LMNACES2CES1TDP1
SCHEMBL5686249 0.79 LMNA (0.47) ALDH1A1LMNACES2CES1TDP1
SCHEMBL22951449 0.79 LMNA (0.47) ALDH1A1LMNACES2CES1TDP1
SCHEMBL5686247 0.79 LMNA (0.47) ALDH1A1LMNACES2CES1TDP1
SCHEMBL10802341 0.75 FURIN (0.61) ALDH1A1LMNACES2CES1TDP1
SCHEMBL11961836 0.73 ALDH1A1 (0.46) ALDH1A1LMNACES2CES1TDP1
SCHEMBL11947946 0.73 ALDH1A1 (0.46) ALDH1A1LMNACES2CES1TDP1
SCHEMBL514858 0.73 CA9 (0.56) ALDH1A1LMNACES2CES1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052476-B1 SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) 2020-07-15 EP disclosed